A 12-Week Randomized, Open-label, Multicenter Trial to Evaluate the Efficacy, Safety, and Tolerability of ZD4522 (80 mg) and the Combination of ZD4522 (80 mg) and Cholestyramine (16 g) in the Treatment of Subjects with Severe Hypercholesterolemia.
Study identifier:4522IL/0031
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A 12-Week Randomized, Open-label, Multicenter Trial to Evaluate the Efficacy, Safety, and Tolerability of ZD4522 (80 mg) and the Combination of ZD4522 (80 mg) and Cholestyramine (16 g) in the Treatment of Subjects with Severe Hypercholesterolemia.
Medical condition
hypercholesterolaemia
Phase
N/A
Healthy volunteers
-
Study drug
-
Sex
-
Actual Enrollment
-
Study type
Interventional
Age
-
Date
Study Start Date: 01 Jan 1971
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
